JPRN-jRCT2031230298招募中1 期
A Phase 1 First-in-human Study of BMS-986406 as Monotherapy and Combination Therapies in Participants with Advanced Malignant Tumors
Walker Justin0 个研究点目标入组 154 人开始时间: 2023年8月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 154
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Part1A,1B,1C;
- •Histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent malignant tumor. Eligible tumor types are non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction, castration-resistant prostate cancer (CRPC), ovarian, squamous cell carcinoma of the head and neck (SCCHN), bladder, melanoma, mesothelioma, triple negative breast cancer (TNBC), and soft tissue sarcoma, except for participants with tumors with central nervous system (CNS) metastases as the only site of active disease
- •Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) of non-squamous or squamous histology with Stage IV A/B (as defined by the 8th International Association for the Study of Lung Cancer Classification) or recurrent disease following multi-modal therapy for locally advanced disease, who have not had systemic therapy for metastatic or recurrent disease.
- •-Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), Prostate Cancer Working Group 3 (PCWG3) (for prostate cancer), or modified Response Evaluation Criteria in Solid tumors (mRECIST) (for mesothelioma)
- •-Eastern Cooperative Oncology Group Performance Status of 0 or 1
- •-Adequate organ function
排除标准
- •-Prior organ or tissue allograft
- •-Leptomeningeal metastases
- •-Untreated CNS metastases
- •-Serious or uncontrolled medical disorders
研究者
相似试验
已完成
1 期
A Study to Evaluate the Safety and Tolerability of Monoclonal Antibody BMS-986207 Alone and in Combination With Nivolumab in Advanced (Solid Tumor) CancersBroad Solid TumorJPRN-jRCT2080223478Bristol-Myers Squibb K.K.170
进行中（未招募）
1 期
Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors.EUCTR2017-000597-11-PLBristol-Myers Squibb International Corporation600
进行中（未招募）
1 期
Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors.EUCTR2017-000597-11-ROBristol-Myers Squibb International Corporation600
进行中（未招募）
1 期
Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors.Advanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2017-000597-11-NLBristol-Myers Squibb International Corporation600
进行中（未招募）
1 期
Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors.Advanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2017-000597-11-NOBristol-Myers Squibb International Corporation600